| Saudi Arabia Pharmaceutical Quality Management Software Market Forecast and Opportunities, 2030F Featuring MasterControl, AmpleLogic, Pilgrim, Sparta Systems, Dassault, Veeva Systems, and Ideagen |
The Saudi Arabia Pharmaceutical Quality Management Software Market is projected to grow from USD 14.48 Million in 2024 to USD 26.92 Million by 2030, with a CAGR of 10.85%. This growth is driven by the expansion of the pharmaceutical industry and the increasing adoption of digital solutions like AI and cloud computing to enhance quality control. Compliance with strict regulatory standards and the push towards automation are also key factors in the market's development. Vision 2030 initiatives further boost the demand for innovative PQMS solutions to support the burgeoning pharmaceutical sector. The Saudi Arabia Pharmaceutical Quality Management Software Market is projected to grow from USD 14.48 Million in 2024 to USD 26.92 Million by 2030, with a CAGR of 10.85%. This growth is driven by the expansion of the pharmaceutical industry and the increasing adoption of digital solutions like AI and cloud computing to enhance quality control. Compliance with strict regulatory standards and the push towards automation are also key factors in the market's development. Vision 2030 initiatives further boost the demand for innovative PQMS solutions to support the burgeoning pharmaceutical sector. |
globenewswire.com |
2025-05-16 10:56:00 |
Czytaj oryginał (ang.) |
| Baron Fifth Avenue Growth Fund Q1 2025 Top Contributors And Detractors |
xAI Holdings led performance with rapid AI innovation, Grok 3 launch, and the acquisition of X, positioning it as an AI industry leader. MercadoLibre delivered strong revenue and margin growth, reinforcing confidence in its leadership in Latin American e-commerce and fintech. Nvidia, despite a stock correction, remains a high-conviction holding due to its dominant AI platform and robust datacenter growth. |
seekingalpha.com |
2025-05-15 11:35:00 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Stock Dips While Market Gains: Key Facts |
In the most recent trading session, Veeva Systems (VEEV) closed at $240.30, indicating a -0.37% shift from the previous trading day. |
zacks.com |
2025-05-14 22:50:50 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Rises But Trails Market: What Investors Should Know |
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $239.53, denoting a +0.51% change from the preceding trading day. |
zacks.com |
2025-05-08 22:45:28 |
Czytaj oryginał (ang.) |
| Veeva to Release Fiscal 2026 First Quarter Results on May 28, 2025 |
PLEASANTON, Calif. , May 7, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its first quarter, which ended April 30, 2025, after market close on May 28, 2025. |
prnewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit |
AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, and more share strategies for more connected customer experiences across sales, marketing, and medical PLEASANTON, Calif. , May 6, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced its keynote speakers for the 2025 Veeva Commercial Summit, May 13-14 in Boston. |
prnewswire.com |
2025-05-06 11:03:00 |
Czytaj oryginał (ang.) |
| Veeva: Our 2025 Software Pick Just Keeps Winning |
I believe Veeva's robust product roadmap, including the introduction of Veeva AI, should deepen adoption and drive productivity across its Development and Commercial Cloud segments. Despite a projected revenue growth slowdown in FY26, Veeva's management remains confident in achieving its $6B revenue target by 2030. VEEV's strong financial discipline is evident, with non-GAAP operating margins expected to expand to 43% in FY26 despite a projected revenue slowdown. |
seekingalpha.com |
2025-05-06 10:51:52 |
Czytaj oryginał (ang.) |
| Life Science Analytics Market worth $68.81 billion by 2030 11.4% CAGR | MarketsandMarkets™ |
DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued at US$35.69 billion in 2024, is forecasted to grow at a robust CAGR of 11.4%, reaching US$40.03 billion in 2025 and an impressive US$68.81 billion by 2030. The standardization of diverse datasets from sources such as clinical trials, electronic health records (EHRs), genomics, and real-world evidence is essential for the efficient exchange of information across various platforms and geographical regions. This standardization enhances multi-site clinical trials and cross-border research collaborations. Additionally, emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights. These technologies help simplify reports and create interactive dashboards. Furthermore, the increasing adoption of analytics in pre-clinical trials, drug discovery, and clinical trials, particularly for applications such as patient recruitment and site identification, helps to reduce the workload for researchers and investigators. These factors contribute significantly to the growing adoption of analytics across the life sciences industry. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653 Browse in-depth TOC on "Life Science Analytics Market" 100 - Tables50 - Figures500 - Pages By Based on type, the life science analytics services market is categorized into two main types: managed services and professional services. In 2024, the managed services segment held the largest share of the life science analytics market. This significant share is largely due to the increasing demand for advanced insights, the need for cost-effective drug development, technological advancements in the industry, and the necessity for ongoing support in strategic decision-making. These factors make outsourcing analytics and consulting more attractive for life science companies. Leading companies in the field offer consulting services that leverage data and analytics to evaluate opportunities, design analytics strategies, and implement appropriate technology solutions. For instance, in May 2023, SAS Institute (US) partnered with HTEC (US) to deliver strategic analytics consulting services across various sectors, including life sciences and healthcare. By Based on applications, The life science analytics market is divided into several applications, including research & development, commercial analytics, regulatory compliance, manufacturing and supply chain optimization, and safety. In 2024, the research & development segment held the largest share of this market. This significant share is mainly due to its capacity to accelerate drug discovery, optimize clinical trials, and improve research accuracy through advanced data analysis and AI-driven insights. Additionally, factors such as increasing R&D expenditure in the pharmaceutical and biopharmaceutical sectors, a rise in patent expirations and declining drug pipelines, and a growing focus on personalized medicine and precision therapeutics are further driving growth in this segment. By geography, the life science analytics market is divided into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience significant growth, with a noticeable annual growth rate during the forecast period. Key factors driving the expansion of life science analytics solutions in this region include a gradual shift towards adopting advanced technologies such as automation, artificial intelligence (AI), and machine learning (ML). Additionally, rising investments are attracting new market players, and the presence of leading educational institutions and research centers in Asia Pacific is fostering scientific innovation and technological advancement. Furthermore, increased direct investments from pharmaceutical and biotechnology companies in Europe and North America are anticipated to boost the adoption of life science analytics solutions in Asia. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=174990653 Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), Optum (US), Microsoft (US), MaxisIT (US), ExlService Holdings (US), Inovalon (US), CitiusTech (US), Saama (US), Axtria (US), Clarivate (UK), ThoughtSphere (US), ThoughtSpot (US), Salesforce (US), Google LLC (US), Amazon Web Services, Inc. (US), Veeva Systems (US), Elsevier (Netherlands), and Komodo Health, Inc. (US) are the major players in this market. These companies mainly focus on strategies such as acquisitions, collaborations, partnerships, expansion, and product launches and updates to remain competitive and further increase their share in the market. ORACLE (US): Oracle (US) is a leading company in life science analytics worldwide. The company offers analytics software and services for various applications, including research & development, commercialization, and more. Oracle is committed to continuously updating its products to meet customer expectations. Additionally, the company invests in expanding its solutions through partnerships and collaborations, ensuring tailored solutions for its users. In March 2025, Oracle partnered with Huntsville Hospital Health System (US) to standardize its Oracle Health Foundation electronic health record system across all facilities. This collaboration aims to provide consistent, high-quality care and a unified experience for both patients and providers as they move between different locations. With a broad customer base and a significant geographic presence, Oracle is a critical player in various IT software, hardware, and service markets, including life science analytics. MERATIVE (US): Merative (US) is another leading player in the life science analytics market. The company offers a comprehensive suite of informatics products and services tailored for life science analytics. By leveraging advanced technologies such as AI and ML, Merative enhances the accuracy and efficiency of evidence analysis. Its strong brand recognition and extensive product portfolio have significantly contributed to its success. Merative serves various sectors, including life science systems, clinical trial sponsors, and the medical device manufacturing industry. Additionally, the company has established offices across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. SAS INSTITUTE INC. (US) SAS Institute Inc. (US) is a company that specializes in analytics software and services. It offers a wide range of solutions, including advanced analytics, business intelligence, cloud analytics, customer intelligence, data operations, data management, decision management, fraud and security intelligence, in-memory analytics, performance management, risk management, and supply chain management. These solutions enable organizations to access, manage, analyze, and report on data to support informed decision-making. SAS Institute serves various industries, including communications, education, financial services, government, health insurance, healthcare, hospitality, insurance, life sciences, manufacturing, media, oil and gas, retail, travel and transportation, and utilities. Through its Life Sciences industry segment, the company also provides specialized analytics solutions for the life sciences sector. By leveraging AI and analytics driven by fast and relevant data, SAS aims to propel innovation in health and life sciences. The company supports customers in 146 countries across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. More than 82,000 business, government, and university sites utilize SAS OnDemand for Academics. For more information, Inquire Now! Related Reports: Healthcare Analytics Market Healthcare BPO Market Healthcare IT Market Artificial Intelligence (AI) in Healthcare Market Healthcare Data Monetization Market Get access to the latest updates on Life Science Analytics Companies and Life Science Analytics Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-05-02 14:30:00 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors |
Veeva Systems (VEEV) closed the most recent trading day at $232.07, moving -0.69% from the previous trading session. |
zacks.com |
2025-05-01 22:50:53 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know |
Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-04-30 14:05:52 |
Czytaj oryginał (ang.) |
| Announcing Veeva AI |
Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial PLEASANTON, Calif. , April 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve employee productivity using AI Agents and AI Shortcuts. |
prnewswire.com |
2025-04-29 11:03:00 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors |
Veeva Systems (VEEV) closed the most recent trading day at $227.11, moving -0.26% from the previous trading session. |
zacks.com |
2025-04-25 22:50:35 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add Veeva Stock to Your Portfolio Now |
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock. |
zacks.com |
2025-04-24 18:05:34 |
Czytaj oryginał (ang.) |
| 3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era |
Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension. |
zacks.com |
2025-04-21 10:40:33 |
Czytaj oryginał (ang.) |
| Wall Street Bulls Look Optimistic About Veeva (VEEV): Should You Buy? |
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. |
zacks.com |
2025-04-18 14:35:45 |
Czytaj oryginał (ang.) |
| Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next |
Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded tariffs on imported goods from most countries for 90 days. |
fool.com |
2025-04-18 10:30:00 |
Czytaj oryginał (ang.) |
| Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock |
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-04-17 14:06:09 |
Czytaj oryginał (ang.) |
| Flatiron Health Joins Veeva's Product Partner Program to Accelerate Oncology Clinical Research |
NEW YORK--(BUSINESS WIRE)--Flatiron Health, a healthtech company transforming clinical research through solutions that integrate research into everyday care, today announced they will partner with Veeva Systems, a global leader in cloud software for the life sciences industry. As part of the partnership, Flatiron Health will join the Veeva Product Partner Program. This collaboration builds on the integration of Flatiron Clinical Pipe™ and Veeva EDC (Electronic Data Capture), enhancing value and. |
businesswire.com |
2025-04-16 13:00:00 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note |
Veeva Systems (VEEV) closed the most recent trading day at $222.72, moving -0.42% from the previous trading session. |
zacks.com |
2025-04-15 22:55:34 |
Czytaj oryginał (ang.) |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar |
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now. |
zacks.com |
2025-04-11 13:55:34 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know |
Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-02-27 12:05:44 |
Czytaj oryginał (ang.) |
| Veeva Direct Data API Now Included with Vault Platform to Enable AI Innovation |
PLEASANTON, Calif. , Feb. 27, 2025 /PRNewswire/ -- Further enabling AI innovation for the life sciences industry, Veeva Systems (NYSE: VEEV) today announced that Direct Data API is now included for no additional license fee as part of Veeva Vault Platform. |
prnewswire.com |
2025-02-27 09:03:00 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Stock Drops Despite Market Gains: Important Facts to Note |
Veeva Systems (VEEV) closed the most recent trading day at $229.19, moving -1.56% from the previous trading session. |
zacks.com |
2025-02-19 20:51:08 |
Czytaj oryginał (ang.) |
| Compliance Group Joins Veeva Services Partner Program to Deliver Implementation Support, Validation, and Post-Implementation Support Services |
LIBERTYVILLE, Ill.--(BUSINESS WIRE)-- #CSA_Validation--Compliance Group Joins Veeva Services Partner Program to Deliver Implementation Support, Validation, and Post-Implementation Support Services. |
businesswire.com |
2025-02-19 10:30:00 |
Czytaj oryginał (ang.) |
| Veeva to Release Fiscal 2025 Fourth Quarter and Full Year Results on March 5, 2025 |
PLEASANTON, Calif. , Feb. 12, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2025, after market close on March 5, 2025. |
prnewswire.com |
2025-02-12 18:05:00 |
Czytaj oryginał (ang.) |
| Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock |
Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-02-12 12:06:19 |
Czytaj oryginał (ang.) |
| Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic? |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-02-11 12:31:31 |
Czytaj oryginał (ang.) |
| Here's Why Veeva Systems (VEEV) Gained But Lagged the Market Today |
In the latest trading session, Veeva Systems (VEEV) closed at $237.81, marking a +0.26% move from the previous day. |
zacks.com |
2025-02-10 20:46:10 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Rises As Market Takes a Dip: Key Facts |
Veeva Systems (VEEV) closed the most recent trading day at $233.29, moving +0.01% from the previous trading session. |
zacks.com |
2025-02-03 20:50:41 |
Czytaj oryginał (ang.) |
| DNAnexus Expands Relationship with Veeva to Advance Global Regulatory Collaboration |
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- #DataSecurity--DNAnexus is expanding its relationship with Veeva to advance global regulatory collaboration in the cloud. |
businesswire.com |
2025-02-03 10:03:00 |
Czytaj oryginał (ang.) |
| Is Trending Stock Veeva Systems Inc. (VEEV) a Buy Now? |
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-01-29 12:05:50 |
Czytaj oryginał (ang.) |
| More Than 200 Companies Advance Trial Management with Veeva CTMS |
Biopharmas use leading CTMS for improved trial efficiency and collaboration PLEASANTON, Calif. , Jan. 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 200 companies – including 17 of the top 20 biopharmas – use Veeva CTMS to execute faster, more efficient trials. |
prnewswire.com |
2025-01-29 09:03:00 |
Czytaj oryginał (ang.) |
| Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now |
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock. |
zacks.com |
2025-01-28 13:21:34 |
Czytaj oryginał (ang.) |
| Veeva Systems: Forget The Short-Term Volatility; The Long Term Is Promising |
I rate Veeva Systems as a 'Buy' due to its strong performance recovery, despite competition from Salesforce and industry uncertainties under Trump's administration. VEEV's migration to its own CRM, Veeva Vault, is a long-term tailwind, enhancing its ecosystem and competitive edge. The Company's Q3 2025 results exceeded expectations, with significant revenue, net income, and free cash flow growth, raising FY 2025 guidance. |
seekingalpha.com |
2025-01-28 07:18:27 |
Czytaj oryginał (ang.) |
| VEEV Stock Falls Despite Tie-Up to Streamline Customers' Operations |
Veeva Systems aims to simplify master data configuration during LIMS implementation and site deployment and enable companies to advance beyond legacy QC systems. |
zacks.com |
2025-01-27 14:35:26 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Ascends While Market Falls: Some Facts to Note |
Veeva Systems (VEEV) reachead $223.40 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close. |
zacks.com |
2025-01-24 20:55:17 |
Czytaj oryginał (ang.) |
| Veeva and Zifo Partner to Accelerate Quality Control Modernization |
Integration will reduce the burden of master lab data configuration, lowering costs and speeding Veeva LIMS implementation PLEASANTON, Calif. and DEERFIELD, Ill. |
prnewswire.com |
2025-01-23 09:03:00 |
Czytaj oryginał (ang.) |
| 2 Growth Stocks to Buy in 2025 and Hold for a Decade |
Artificial intelligence (AI) was, once again, the hottest investing topic in 2024. It might remain so in 2025, but that doesn't mean there aren't companies in other fields worth investing in. |
fool.com |
2025-01-23 05:45:00 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Advances While Market Declines: Some Information for Investors |
In the most recent trading session, Veeva Systems (VEEV) closed at $214.75, indicating a +1.43% shift from the previous trading day. |
zacks.com |
2025-01-16 20:56:11 |
Czytaj oryginał (ang.) |
| Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know |
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-01-16 12:00:25 |
Czytaj oryginał (ang.) |
| Here's Why Veeva Systems (VEEV) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-12-31 13:01:22 |
Czytaj oryginał (ang.) |
| Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It |
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2024-12-26 12:06:15 |
Czytaj oryginał (ang.) |
| Veeva initiated with an Overweight at Stephens |
Stephens analyst Jeff Garro initiated coverage of Veeva with an Overweight rating and $280 price target. The company's sales growth stabilizing in the mid-teens, a return to 40%-plus EBITDA margins, and positive early feedback on the Vault transition have the shares delivering a strong share price performance over the last six months, the analyst tells investors in a research note. The firm says that relative to its own historical valuation multiple, Veeva is trading well below its 10-year average. It believes the company's next leg of growth through the new markets plan has potential to push the multiple back toward its 10-year average. |
https://thefly.com |
2024-12-19 18:23:47 |
Czytaj oryginał (ang.) |
| Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now |
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock. |
zacks.com |
2024-12-17 11:06:09 |
Czytaj oryginał (ang.) |
| Got $5,000? 3 Tech Stocks to Buy and Hold for the Long Term. |
Technology not only helps to improve our lives but also provides us with easier access to our loved ones. The digitization wave has prompted individuals and corporations to embrace cloud computing, while the emergence of generative artificial intelligence (AI) has seen an explosion in new uses. |
fool.com |
2024-12-14 09:30:00 |
Czytaj oryginał (ang.) |
| Why Veeva Systems (VEEV) is a Top Growth Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-12-12 12:46:07 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know |
Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-12-12 12:05:35 |
Czytaj oryginał (ang.) |
| A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization |
Modern commercial data helps organizations find new patients and HCPs PLEASANTON, Calif. , Dec. 12, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Compass Patient, an emerging leader for anonymous patient longitudinal data. |
prnewswire.com |
2024-12-12 09:03:00 |
Czytaj oryginał (ang.) |
| 2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond |
The stock market performed well in 2024 despite lingering economic issues and geopolitical instability. The bull run remains in full swing, and although investors can't predict what will happen in 2025, it is still worth investing in stocks. |
fool.com |
2024-12-12 06:07:00 |
Czytaj oryginał (ang.) |
| Deciphering Veeva (VEEV) International Revenue Trends |
Explore how Veeva's (VEEV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. |
zacks.com |
2024-12-11 12:16:03 |
Czytaj oryginał (ang.) |
| Veeva Delivers Vault CRM Suite with Vault CRM Campaign Manager |
Latest release of Veeva Vault CRM Suite connects engagement across sales, marketing, and medical PLEASANTON, Calif. , Dec. 10, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the newest release of Vault CRM Suite, the market-leading CRM system for life sciences. |
prnewswire.com |
2024-12-10 17:02:00 |
Czytaj oryginał (ang.) |
| Veeva to Present at Upcoming Investor Conference |
PLEASANTON, Calif. , Dec. 9, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conference: Raymond James 2024 TMT and Consumer Conference, New York, NY. |
prnewswire.com |
2024-12-09 12:30:00 |
Czytaj oryginał (ang.) |
| Veeva Systems Q3 Earnings & Revenues Beat, Operating Margin Up Y/Y |
VEEV's fiscal third-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins. |
zacks.com |
2024-12-09 08:47:37 |
Czytaj oryginał (ang.) |
| Veeva Systems: Normalization Of Macro Environment Is Positive For VEEV |
I am positive on Veeva Systems (VEEV) due to expected growth acceleration as demand normalizes and strong product adoption continues. VEEV's latest earnings report showed impressive revenue growth and margin expansion, with upward revisions in FY25 guidance. The macro environment is stabilizing, which should benefit VEEV, as evidenced by improved demand visibility and positive industry comments. |
seekingalpha.com |
2024-12-06 11:43:49 |
Czytaj oryginał (ang.) |
| Veeva Systems Q3: Making Progress With Vault CRM; Reiterating 'Strong Buy' |
Veeva Systems shows strong growth with 13.4% revenue and 30% adjusted operating income increases, driven by successful Vault CRM migration and new customer acquisitions. The company is expanding AI offerings within Vault CRM, including CRM Bot, GenAI assistant, and Voice Control, enhancing customer experience and retention. VEEV's FY25 revenue growth is projected at over 15%, with a one-year target price of $270 per share, supported by a stable funding environment. |
seekingalpha.com |
2024-12-06 02:10:16 |
Czytaj oryginał (ang.) |
| Veeva Systems Inc. (VEEV) Q3 2025 Earnings Call Transcript |
Veeva Systems Inc. (NYSE:VEEV ) Q3 2025 Earnings Conference Call December 5, 2024 5:00 PM ET Company Participants Gunnar Hansen - Director, Investor Relations Peter Gassner - Chief Executive Officer Paul Shawah - Executive Vice President, Strategy Brian Van Wagener - Chief Financial Officer Conference Call Participants Saket Kalia - Barclays Ken Wong - Oppenheimer Joe Vruwink - Baird Brian Peterson - Raymond James Ryan MacDonald - Needham and Company Anne Samuel - J.P. Morgan Dave Windley - Jefferies Gabriela Borges - Goldman Sachs Brent Bracelin - Piper Sandler Stan Berenshteyn - Wells Fargo Tyler Radke - Citi Craig Hettenbach - Morgan Stanley DJ Hynes - Canaccord Jailendra Singh - Truist Securities Andrew DeGasperi - BNP Paribas David Larsen - BTIG Charles Rhyee - TD Cowen Brad Sills - Bank of America Steven Valiquette - Mizuho Securities Operator Thank you for standing by. |
seekingalpha.com |
2024-12-05 22:23:52 |
Czytaj oryginał (ang.) |
| Veeva (VEEV) Reports Q3 Earnings: What Key Metrics Have to Say |
The headline numbers for Veeva (VEEV) give insight into how the company performed in the quarter ended October 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-12-05 21:00:21 |
Czytaj oryginał (ang.) |
| Veeva Systems (VEEV) Q3 Earnings and Revenues Surpass Estimates |
Veeva Systems (VEEV) came out with quarterly earnings of $1.75 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.34 per share a year ago. |
zacks.com |
2024-12-05 20:26:09 |
Czytaj oryginał (ang.) |
| Veeva Announces Fiscal 2025 Third Quarter Results |
Total Revenues of $699.2M, up 13% Year Over Year Subscription Services Revenues of $580.9M, up 17% Year Over Year PLEASANTON, Calif. , Dec. 5, 2024 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its third quarter ended October 31, 2024. |
prnewswire.com |
2024-12-05 18:05:00 |
Czytaj oryginał (ang.) |
| Veeva initiated with an Outperform at Mizuho |
Mizuho initiated coverage of Veeva with an Outperform rating and $275 price target. The firm says Veeva remains the market share leader in life science commercial and development cloud solutions. It expects the company's mid-teens sales to continue through fiscal 2028, noting the company is only 14% penetrated in its $20B total addressable market. Veeva's total revenue growth has rebounded this year, as the secular softening of end customer spending has slowly improved, the analyst tells investors in a research note. |
https://thefly.com |
2024-12-03 18:30:15 |
Czytaj oryginał (ang.) |